Response of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib.
Department of Dermatology, Medical University of Graz, Graz, Austria.
Anna
A
Niederkorn
Werner
W
Wackernagel
Monika
M
Artl
Gerold
G
Schwantzer
Birgit
B
Aigner
Erika
E
Richtig
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D008875:Middle Aged; D009367:Neoplasm Staging; D009536:Niacinamide / Q000008:administration & dosage / Q000031:analogs & derivatives; D009607:Nitrosourea Compounds / Q000008:administration & dosage; D009943:Organophosphorus Compounds / Q000008:administration & dosage; D010671:Phenylurea Compounds / Q000008:administration & dosage; D012189:Retrospective Studies; D000077157:Sorafenib; D015996:Survival Rate; D014604:Uveal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib; C054368:fotemustine